Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
Biogen(BIIB) stock is priced at $187.57, giving the company a market capitalization of 27.5B. It carries a P/E multiple of 20.92.
On 2026-03-31, Biogen(BIIB) stock moved within a range of $185.55 to $190.09. With shares now at $187.57, the stock is trading +1.1% above its intraday low and -1.3% below the session's peak.
Trading activity shows a volume of 771.79K, compared to an average daily volume of 968.49K.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.
BIIB News
BMO Capital analyst Evan Seigerman says high-dose Spinraza approval and positive Phase 2 AMETHYST trial data are both “likely positive drivers” of Biogen (BIIB)...
Needham analyst Ami Fadia has maintained their neutral stance on BIIB stock, giving a Hold rating yesterday. End of Quarter Sale - 50% Off TipRanks Unlock hedge...
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Biogen, retaining the price target of $190.00. End of Quarter Sale - 50% Off TipRanks Unlock...
Analyst ratings
54%
of 35 ratingsMore BIIB News
(RTTNews) - Biogen Inc. (BIIB) announced positive results from Part A of the AMETHYST Phase 2/3 study of litifilimab in people living with cutaneous lupus eryth...
Biogen (BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study of litifilimab in people living with cutaneous lupus erythematosu...
In March 2026, Alteogen announced an exclusive license deal giving Biogen rights to develop subcutaneous formulations for two biologic products using ALT-B4 Hyb...
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has completed a Phase 1 study titled “A Randomized, Open-Label, 2-Ar...
Biogen (NasdaqGS:BIIB) has entered an exclusive license agreement with Alteogen for its Hybrozyme (ALT-B4) technology. The deal focuses on developing and comme...
(RTTNews) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has e...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.